{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Study design rationale', 'The proposed design will investigate efficacy, safety, and tolerability of alemtuzumab compared', 'to other DMTs, (ie, IFNB and glatiramer acetate [GA]) in an open-label, rater-blinded, single-arm,', 'before and after switch study, in paediatric patients with RRMS aged from 10 years to less than', '18 years with disease activity on prior DMT, with a rater-blinded MRI endpoint.', 'This study is based on the paediatric investigational plan (PIP) agreed with the European', 'Medicines Agency (EMA) and its Paediatric Committees (PDCO).', 'Patient population', 'The patient population intended for this paediatric study will be narrower than the', 'population described in the adult indication to expose only these paediatric patients with', 'high medical need, having MS disease activity while on treatment with prior DMT.', 'The MS disease activity criteria include having at least 2 recorded MS attacks; at least 1', 'MS relapse in the last year during treatment with an IFNB or GA after having been on that', 'therapy for at least 6 months, and is currently still taking the same therapy; and having', 'either >1 new or enlarging T2 hyperintense lesion or gadolinium enhancing lesion while', 'on that same prior therapy (IFNB or GA), or 2 or more relapses in the prior year, or tried', 'at least 2 MS DMTs.', 'The age group eligible to enroll (from 10 years to less than 18 years) has higher MS prevalence', 'than younger age groups.', 'Interferon-beta (IFNB) and GA have not been formally tested in paediatric MS patients with a', 'relapsing-remitting course during placebo-controlled trials. However, class III and IV evidence of', 'effectiveness resulting from observational open-label studies have prompted their current use and', 'recommendation. Nonetheless, in about 30% of paediatric MS patients, the disease continues to be', 'active despite immunomodulatory treatment, supporting the need to explore other therapeutic', 'options (15). There are few data to support the use of other DMTs in paediatric populations.', 'Considering the high frequency of inadequate response to first-line DMT and the lack of clinical', 'trial data regarding the efficacy of switching to other DMTs, this paediatric population has a high', 'unmet need.', 'Alemtuzumab dose selection', 'Alemtuzumab will be administered as a daily intravenous (IV) infusion, similar to adult treatment', 'regimen (course 1 at Month 0, 12 mg on 5 consecutive days, and course 2 at Month 12, 12 mg on', '3 consecutive days), giving a cumulative dosage of 60 mg at first course, and 36 mg at second', 'course. The adult dose will be adjusted (reduced) proportionately for paediatric patients <50 kg', \"based on the patient's weight. Calculation of a paediatric patient's dose will be based on patient's\", 'last visit weight taken during the physical examination:', 'For patients >50 kg: 12 mg/day.', 'For patients <50 kg: 0.24 mg/kg/day (this equates to 12 mg/day for a 50 kg patient).', 'Property of the Sanofi Group - strictly confidential', 'Page 35', 'VV-CLIN-02544065 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'The 0.24 mg/kg/day dose is based on experience using alemtuzumab in the treatment of children', 'undergoing bone marrow or solid organ transplantation, and is similar to or lower than doses', 'previously used (16). This corresponds to a cumulative dose over 5 days of 1.2 mg/kg at Month 0,', 'with a smaller dose of 0.72 mg/kg at Month 12.', 'Prophylactic administration of methylprednisolone, antiH1 and antiH2 medications will be a part', 'of the alemtuzumab treatment regimen, to minimize infusion associated reactions.', 'MRI', 'The proposed study will have an MRI-based primary endpoint. Recent publications have', 'demonstrated a correlation between the MRI lesions and clinical relapse for IFNB or GA based on', 'meta-analysis of data collected in randomized controlled trials (17), and for alemtuzumab (13).', 'MRI assessments will be available to investigators to assess safety.', 'The period of 4 months for comparison of new or enlarged T2 lesions on prior DMT versus on', 'alemtuzumab was selected on advice of paediatric MS experts as representing the optimum', 'interval to achieve the scientific aims of the study consistent with current patient care practice for', 'children experiencing disease activity while using IFNB or GA.', 'Property of the Sanofi Group - strictly confidential', 'Page 36', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}